Drug Database · Clinicians

Enalapril

Brands (34) Hypace, Scheepril, Enafril…Show all

Angiotensin converting enzyme (ACE) inhibitor; ACE inhibitor; and others PH FDA category

Rx · Prescription drug61 PH productsPNF-listedPhilHealth GAMOTVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 39631f1f-5d19-43c1-b504-bf56d991ed97, version date January 23, 2026 (Vasotec · Bausch Health US LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE Hypertension VASOTEC is indicated for the treatment of hypertension.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE Hypertension VASOTEC is indicated for the treatment of hypertension. VASOTEC is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of VASOTEC and thiazides are approximately additive. Heart Failure VASOTEC is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis.

In these patients VASOTEC improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), VASOTEC decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials).

In using VASOTEC consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that VASOTEC does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis). In considering use of VASOTEC, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks.

In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema).

Contraindications

CONTRAINDICATIONS VASOTEC is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin-converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. Do not coadminister aliskiren with VASOTEC in patients with diabetes (see PRECAUTIONS, Drug Interactions).

VASOTEC is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer VASOTEC within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS, Head and Neck Angioedema).

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Hypertension In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of VASOTEC. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with VASOTEC to reduce the likelihood of hypotension (see WARNINGS, Hypotension).

If the patient’s blood pressure is not controlled with VASOTEC alone, diuretic therapy may be resumed. If the diuretic cannot be discontinued an initial dose of 2.5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see WARNINGS, Hypotension and PRECAUTIONS, Drug Interactions).

The recommended initial dose in patients not on diuretics is 5 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 10 to 40 mg per day administered in a single dose or two divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval.

In such patients, an increase in dosage or twice daily administration should be considered. If blood pressure is not controlled with VASOTEC alone, a diuretic may be added. Concomitant administration of VASOTEC with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see PRECAUTIONS).

Dosage Adjustment in Hypertensive Patients with Renal Impairment The usual dose of enalapril is recommended for patients with a creatinine clearance more than 30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance less than or equal to 30 mL/min (serum creatinine more than or equal to 3 mg/dL), the first dose is 2.5 mg once daily.

The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. Renal Status Creatinine Clearance (mL/min) Initial Dose (mg/day) Normal Renal Function >80 mL/min 5 mg Mild Impairment ≤80 >30 mL/min 5 mg Moderate to Severe Impairment ≤30 mL/min 2.5 mg Dialysis Patients See WARNINGS, Anaphylactoid Reactions During Membrane Exposure. 2.5 mg on dialysis days Dosage on nondialysis days should be adjusted depending on the blood pressure response.

Heart Failure VASOTEC is indicated for the treatment of symptomatic heart failure, usually in combination with diuretics and digitalis. In the placebo-controlled studies that demonstrated improved survival, patients were titrated as tolerated up to 40 mg, administered in two divided doses. The recommended initial dose is 2.5 mg.

The recommended dosing range is 2.5 to 20 mg given twice a day. Doses should be titrated upward, as tolerated, over a period of a few days or weeks. The maximum daily dose administered in clinical trials was 40 mg in divided doses. After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see WARNINGS and PRECAUTIONS, Drug Interactions).

If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. Asymptomatic Left Ventricular Dysfunction In the trial that demonstrated efficacy, patients were started on 2.5 mg twice daily and were titrated as tolerated to the targeted daily dose of 20 mg (in divided doses).

After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see WARNINGS and PRECAUTIONS, Drug Interactions). If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension.

The appearance of hypotension after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see DOSAGE AND ADMINISTRATION, Heart Failure, WARNINGS and PRECAUTIONS, Drug Interactions).

The dose may be increased to 2.5 mg b.i.d. (twice a day), then 5 mg b.i.d (twice a day) and higher as needed, usually at intervals of four days or more if at the time of dosage adjustment there is not excessive hypotension or significant deterioration of renal function. The maximum daily dose is 40 mg. Pediatric Hypertensive Patients The usual recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily.

Dosage should be adjusted according to blood pressure response. Doses above 0.58 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients (see CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients). VASOTEC is not recommended in neonates and in pediatric patients with glomerular filtration rate less than 30 mL/min/1.73 m², as no data are available.

Preparation of Suspension (for 200 mL of a 1.0 mg/mL suspension) Add 50 mL of sodium citrate and citric acid oral solution, USP to a polyethylene terephthalate (PET) bottle containing ten 20 mg tablets of VASOTEC and shake for at least 2 minutes. Let concentrate stand for 60 minutes. Following the 60-minute hold time, shake the concentrate for an additional minute.

Add 150 mL of Ora-Sweet SF to the concentrate in the PET bottle and shake the suspension to disperse the ingredients. The suspension should be refrigerated at 2° to 8°C (36° to 46°F) and can be stored for up to 30 days. Shake the suspension before each use.

Dosing: Altered kidney function

From the US FDA label · Renal impairment (dosage and administration)

Patients with Renal Impairment The usual dose of enalapril is recommended for patients with a creatinine clearance more than 30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance less than or equal to 30 mL/min (serum creatinine more than or equal to 3 mg/dL), the first dose is 2.5 mg once daily.

The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. Renal Status Creatinine Clearance (mL/min) Initial Dose (mg/day) Normal Renal Function >80 mL/min 5 mg Mild Impairment ≤80 >30 mL/min 5 mg Moderate to Severe Impairment ≤30 mL/min 2.5 mg Dialysis Patients See WARNINGS, Anaphylactoid Reactions During Membrane Exposure. 2.5 mg on dialysis days Dosage on nondialysis days should be adjusted depending on the blood pressure response.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Neonates with a History of In Utero Exposure to VASOTEC If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.

Antihypertensive effects of VASOTEC have been established in hypertensive pediatric patients age 1 month to 16 years. Use of VASOTEC in these age groups is supported by evidence from adequate and well-controlled studies of VASOTEC in pediatric and adult patients as well as by published literature in pediatric patients (see CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients and DOSAGE AND ADMINISTRATION).

VASOTEC is not recommended in neonates and in pediatric patients with glomerular filtration rate <30 mL/min/1.73 m², as no data are available.

Dosage forms

Philippines

  • Tablet: 5 mg, 10 mg, 20 mg
  • Film-coated tablet: 5 mg

Registered products in the Philippines

61 products registered with the Food and Drug Administration (FDA) Philippines list Enalapril as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products61
Philippine FDA-registered products for Enalapril
Package insert
Angiopril 5Enalapril maleate maleate
5 mg TabletAlu/Alu Strip Pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Healthcare Ltd.India
GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.
DRP-15204-02
May 24, 2029
AzeprilEnalapril maleate
5 mg TabletAmber PVC and printed silver aluminum foil x 10's (Box of 100's)
RxVAT-exempt
Centurion Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Philgen Pharmaceuticals Inc.
DRP 3148
May 15, 2030
BenzadiqEnalapril maleate
20 mg TabletAlu/PVC Blister Pack x 10's Box of 30's
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-9180
Sep 30, 2030
Dianapril-10Enalapril Maleate
10 mg TabletAlu/Alu Blister Pack x 10’s Box of 100’s
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-2322-01
Dec 1, 2029
Dianapril-5Enalapril Maleate
5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-3010-01
Dec 10, 2029
EnafrilEnalapril Maleate
10 mg TabletAlu/PVC Blister Pack x 10's (Box of 10's)
RxVAT-exempt
Nanjing Baijingyu Pharmaceutical Co., Ltd.China
Global Pharmatrade
DR-XY43850
Oct 30, 2029
EnafrilEnalapril (as maleate)
5 mg TabletPVC/Alu Blister Pack x 10's (Box of 10's)
RxVAT-exempt
Nanjing Baijingyu Pharmaceutical Co., Ltd.China
Global Pharmatrade
DR-XY44658
Jul 7, 2030
Enalared 10Enalapril maleate
10 mg TabletAlu/Alu Blister Pack of 10’s (Box of 100’s)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Roymed PharmaceuticalImporter: Ollen Pharma Trading, Inc.
DRP-14958-01
Oct 20, 2030
Enaprimed-10Enalapril maleate
10mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Saga Lifesciences LimitedIndia
Medinova Pharmaceutical, Inc
DRP-13931
May 18, 2028
Enaprimed-5Enalapril maleate
5 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's)
RxVAT-exempt
Saga Lifesciences LimitedIndia
Medinova Pharmaceutical Inc.
DRP-13662
Mar 23, 2028
Enaprinova-10Enalapril maleate
10 mg TabletAlu/Alu Strip Pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Healthcare Ltd.India
Medinova Pharmaceutical Inc.
DRP-15205
May 24, 2029
Enaprinova-5Enalapril maleate
5 mg TabletAlu/Alu Strip Pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Healthcare Ltd.India
Medinova Pharmaceutical Inc.
DRP-15204
May 24, 2029
Enara 10Enalapril
10 mg TabletAlu/Alu Foil Strip x 4's (Box of 28's)
RxVAT-exempt
Huazhong Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.
DRP-16251
Jan 13, 2030
Enara 20Enalapril
20 mg TabletAlu/Alu Foil Strip x 4's (Box of 28's)
RxVAT-exempt
Huazhong Pharmaceutical Co., Ltd.
AMB HK Enterprises Inc.
DRP-16250
Jan 13, 2030
Enara 5Enalapril
5 mg TabletAlu/Alu Foil Strip x 4's (Box of 28's)
RxVAT-exempt
Huazhong Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-16252
Jan 13, 2030
EnbidEnalapril Maleate
5 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 20’s and 100’s)
RxVAT-exempt
Agio Pharmaceuticals Ltd.India
Ambica International Corporation
DRP-2919
Apr 29, 2029
Enbid-10Enalapril Maleate
10 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 20’s)
RxVAT-exempt
Agio Pharmaceuticals Ltd.India
Ambica International Corporation
DRP-4557
Jan 30, 2038
HypaceEnalapril maleate
10 mg TabletAlu/Alu Foil Strip x 4's (Box of 28's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Trader: Pascual Pharma Corporation
DR-XY27383
Mar 30, 2031
HypaceEnalapril maleate
20 mg TabletAlu/Alu Foil Strip x 4's (Box of 28's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Trader: Pascual Pharma Corporation
DR-XY27380
Mar 30, 2031
HypaceEnalapril maleate
5 mg TabletAlu/Alu Foil Strip x 4's (Box of 28's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Trader: Pascual Pharma Corporation
DR-XY27382
Mar 30, 2031
HyprilEnalapril (as Maleate)
10 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's and 30's)
RxVAT-exempt
Intas Pharmaceuticals LimtedIndia
Phil Pharmawealth, Inc.
DR-XY29669
Jun 7, 2029
HyprilEnalapril (as Maleate)
5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Intas Pharmaceuticals LimitedIndia
Phil Pharmawealth, Inc.
DR-XY29668
Jun 7, 2029
NaprilateEnalapril Maleate
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
TAIWAN BIOTECH CO., LTD.Taiwan
NEW SMART FORMULAE TRADING CORP.
DR-XY44387
Mar 30, 2027
NaprilateEnalapril Maleate
5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Taiwan Biotech Co., Ltd.Taiwan
New Smart Formulae Trading Corp.
DR-XY44386
Mar 30, 2027
NoneEnalapril Maleate
10 mg TabletAlu/Alu Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Pascual Laboratories, Inc.Philippines
Ritemed Phils., Inc.
DR-XY29779
Apr 24, 2027
NoneEnalapril maleate
10 mg TabletAlu/Alu Strip Pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Healthcare Ltd.India
Qualifirst Health Inc.Importer: Medinova Pharmaceutical Inc.
DRP-15205-01
May 24, 2029
NoneEnalapril maleate
10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-2552-01
Oct 20, 2028
NoneEnalapril maleate
10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
PharmaVital Corp.Importer: Ambica International Corporation
DRP-2552-02
Oct 20, 2028
NoneEnalapril Maleate
10 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 20’s)
RxVAT-exempt
Agio Pharmaceuticals Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-4557-01
Sep 11, 2037
NoneEnalapril Maleate
10 mg TabletStrip Foil x 10's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DRP-6788
Jun 16, 2027
NoneEnalapril Maleate
10mg TabletAluminum Strip Foil x 10's Box of 100's
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
TGP Pharma Inc.
DRP-6788-01
Jun 16, 2027
NoneEnalapril Maleate
20 mg TabletAlu/PVC Blister Pack x 10's (Box of 30’s)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-3268-02
Sep 21, 2031
NoneEnalapril Maleate
20 mg TabletAluminum Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Pascual Laboratories, Inc.Philippines
Ritemed Phils., Inc.
DRP-7847
Apr 24, 2027
NoneEnalapril maleate
20 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Pharma Vital Corp.Importer: Ambica International Corporation
DRP-9180-01
Sep 30, 2030
NoneEnalapril Maleate
5 mg TabletAlu/Alu Foil Strip x 10's (Box of 100's)
RxVAT-exempt
Pascual Laboratories, Inc.Philippines
Ritemed Phils., Inc.
DR-XY29746
Apr 24, 2027
NoneEnalapril Maleate
5 mg TabletAlu/Alu Strip Pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Healthcare Ltd.India
Qualifirst Health Inc.Importer: Medinova Pharmaceutical Inc.
DRP-15204-03
May 24, 2029
NoneEnalapril Maleate
5 mg TabletAlu/ Clear PVC Blister Pack x 10’s (Box of 20’s)
RxVAT-exempt
Agio Pharmaceuticals Ltd.India
Actimed, Inc.Importer: Ambica International Corporation
DRP-2919-01
Apr 29, 2029
NoneEnalapril (as maleate)
5 mg TabletAluminum Strip Foil x 10's (Box of 100's)
RxVAT-exempt
Drugmaker's Laboratories, Inc.Philippines
—
DRP-6230
Nov 15, 2030
NormbeatEnalapril Maleate
20 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-3268-01
Aug 13, 2037
Normbeat 10Enalapril Maleate
10 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-2322-02
Dec 1, 2029
Normbeat 5Enalapril Maleate
5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
TGP Pharma Inc.Importer: Ambica International Corporation
DRP-3010-02
Dec 10, 2029
Ollepril-10Enalapril maleate
10 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Ollen Pharma Trading, Inc.,
DRP-14958
Oct 20, 2030
Ollepril-20Enalapril maleate
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Ollen Pharma Trading, Inc.
DRP-14957
Oct 20, 2030
Renilyf 10Enalapril Maleate
10 mg TabletAlu / Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-2322-03
Dec 1, 2029
Renilyf 5Enalapril Maleate
5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-3010-03
Dec 10, 2029
Renite XLEnalapril Maleate
10 mg TabletAlu/Alu Blister Pack x 10’s Box of 100’s
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-2322
Dec 1, 2029
Renite-5 XLEnalapril Maleate
5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
XL Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-3010
Dec 10, 2029
RetanaprilEnalapril maleate
5 mg TabletAlu/Alu Strip Pack x 10's (Box of 100's)
RxVAT-exempt
S Kant Healthcare Ltd.India
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-15204-01
May 24, 2029
SaphprilEnalapril maleate
5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Genom Biotech Pvt. Ltd.India
Ollen Pharma Trading Inc.
DRP-17853
Mar 25, 2031
ScheeprilEnalapril Maleate
10 mg TabletBlister pack x 10's (Box of 100's)
RxVAT-exempt
Scheele Laboratories Phils., Inc.Philippines
—
DRP-1081
May 9, 2032
ScheeprilEnalapril Maleate
20 mg TabletBlister Pack x 10's (Box of 100's)
RxVAT-exempt
Scheele Laboratories Phils., Inc.Philippines
—
DRP-1078
Jul 6, 2027
ScheeprilEnalapril Maleate
5 mg TabletBlister Pack x 10's (Box of 100's)
RxVAT-exempt
Scheele Laboratories Phils., Inc.Philippines
—
DRP-1079
Jul 6, 2027
Stalpril - 20Enalapril Maleate
20 mg TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-3268
Sep 21, 2030
Stalpril-10Enalapril maleate
10 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-2552
Oct 20, 2028
UnbrandedEnalapril Maleate
10 mg TabletBlister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Hizon Laboratories, Inc.Rizal
—
DRP-346
Oct 5, 2031
UnbrandedEnalapril Maleate
10 mg TabletBlister Pack x 10’s (Box of 100’s)
RxVAT-exempt
Hizon Laboratories, Inc.Rizal
Actimed, Inc.
DRP-346-03
Oct 5, 2036
UnbrandedEnalapril Maleate
20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
—
DR-XY46957
Jul 30, 2030
VasotecEnalapril Maleate
10 mg Tablet
RxVAT-exempt
Lloyd Laboratories, Inc.
TGP Pharma Inc.Trader: D.B. Manix International, Inc.
DR-XY35306
Jan 13, 2027
VasotecEnalapril Maleate
20 mg TabletAlu/ Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma, Inc.Trader: D.B. Manix International, Inc.
DR-XY40042
Sep 15, 2031
(no brand name)Enalapril Maleate
10 mg TabletAlu/Clear PVC Blister Pack x 10's (Box of 20's))
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-14024
Jun 6, 2028
(no brand name)Enalapril maleate
5 mg TabletAlu/PVC Blister Pack x 10's (Box of 2 Blister packs x 10 Tablets)
RxVAT-exempt
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-13631
Mar 21, 2028

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label

WARNINGS Anaphylactoid and Possibly Related Reactions Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including VASOTEC) may be subject to a variety of adverse reactions, some of them serious. Head and Neck Angioedema Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin-converting enzyme inhibitors, including VASOTEC.

This may occur at any time during treatment. In such cases VASOTEC should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms.

Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS).

Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS). Intestinal Angioedema: Intestinal angioedema has been reported in patients treated with ACE inhibitors.

These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor.

Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain. Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see INDICATIONS AND USAGE and CONTRAINDICATIONS).

Anaphylactoid Reactions During Desensitization Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.

Anaphylactoid Reactions During Membrane Exposure Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.

Hypotension Excessive hypotension is rare in uncomplicated hypertensive patients treated with VASOTEC alone. Patients with heart failure given VASOTEC commonly have some reduction in blood pressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy (see DOSAGE AND ADMINISTRATION).

Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high-dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic (except in patients with heart failure), reduce the diuretic dose or increase salt intake cautiously before initiating therapy with VASOTEC in patients at risk for excessive hypotension who are able to tolerate such adjustments (see PRECAUTIONS, Drug Interactions and ADVERSE REACTIONS).

In patients at risk for excessive hypotension, therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident.

If excessive hypotension occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of VASOTEC, which usually can be given without difficulty once the blood pressure has stabilized.

If symptomatic hypotension develops, a dose reduction or discontinuation of VASOTEC or concomitant diuretic may be necessary. Neutropenia/Agranulocytosis Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease.

Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause agranulocytosis at similar rates. Marketing experience has revealed cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered.

Hepatic Failure Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis, and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.

Fetal Toxicity Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.

When pregnancy is detected, discontinue VASOTEC as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.

Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus.

Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue VASOTEC, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury.

Closely observe infants with histories of in utero exposure to VASOTEC for hypotension, oliguria, and hyperkalemia (see PRECAUTIONS, Pediatric Use). No teratogenic effects of enalapril were seen in studies of pregnant rats and rabbits. On a body surface area basis, the doses used were 57 times and 12 times, respectively, the maximum recommended human daily dose (MRHDD).

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Neprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema (see WARNINGS). Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.

Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on VASOTEC and other agents that affect the RAS. Do not coadminister aliskiren with VASOTEC in patients with diabetes.

Avoid use of aliskiren with VASOTEC in patients with renal impairment (GFR <60 mL/min).

Hypotension — Patients on Diuretic Therapy Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril.

If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (see WARNINGS, Hypotension and DOSAGE AND ADMINISTRATION). Agents Causing Renin Release The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).

Nonsteroidal Anti-Inflammatory Agents Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.

Monitor renal function periodically in patients receiving enalapril and NSAID therapy. In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.

Other Cardiovascular Agents VASOTEC has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions. Agents Increasing Serum Potassium VASOTEC attenuates potassium loss caused by thiazide-type diuretics.

Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.

Potassium-sparing agents should generally not be used in patients with heart failure receiving VASOTEC. Lithium Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs.

It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium. Gold Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. mTOR (Mammalian Target of Rapamycin) Inhibitors Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS, Head and Neck Angioedema).

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS VASOTEC has been evaluated for safety in more than 10,000 patients, including over 1000 patients treated for one year or more. VASOTEC has been found to be generally well tolerated in controlled clinical trials involving 2987 patients. For the most part, adverse experiences were mild and transient in nature.

In clinical trials, discontinuation of therapy due to clinical adverse experiences was required in 3.3 percent of patients with hypertension and in 5.7 percent of patients with heart failure. The frequency of adverse experiences was not related to total daily dosage within the usual dosage ranges. In patients with hypertension the overall percentage of patients treated with VASOTEC reporting adverse experiences was comparable to placebo.

Hypertension Adverse experiences occurring in greater than one percent of patients with hypertension treated with VASOTEC in controlled clinical trials are shown below. In patients treated with VASOTEC, the maximum duration of therapy was three years; in placebo-treated patients the maximum duration of therapy was 12 weeks.

VASOTEC (n=2314) Incidence (discontinuation) Placebo (n=230) Incidence Body As A Whole Fatigue 3.0 (<0.1) 2.6 Orthostatic Effects 1.2 (<0.1) 0.0 Asthenia 1.1 (0.1) 0.9 Digestive Diarrhea 1.4 (<0.1) 1.7 Nausea 1.4 (0.2) 1.7 Nervous/Psychiatric Headache 5.2 (0.3) 9.1 Dizziness 4.3 (0.4) 4.3 Respiratory Cough 1.3 (0.1) 0.9 Skin Rash 1.4 (0.4) 0.4 Heart Failure Adverse experiences occurring in greater than one percent of patients with heart failure treated with VASOTEC are shown below. The incidences represent the experiences from both controlled and uncontrolled clinical trials (maximum duration of therapy was approximately one year).

In the placebo-treated patients, the incidences reported are from the controlled trials (maximum duration of therapy is 12 weeks). The percentage of patients with severe heart failure (NYHA Class IV) was 29 percent and 43 percent for patients treated with VASOTEC and placebo, respectively. VASOTEC (n=673) Incidence (discontinuation) Placebo (n=339) Incidence Body As A Whole Orthostatic Effects 2.2 (0.1) 0.3 Syncope 2.2 (0.1) 0.9 Chest Pain 2.1 (0.0) 2.1 Fatigue 1.8 (0.0) 1.8 Abdominal Pain 1.6 (0.4) 2.1 Asthenia 1.6 (0.1) 0.3 Cardiovascular Hypotension 6.7 (1.9) 0.6 Orthostatic Hypotension 1.6 (0.1) 0.3 Angina Pectoris 1.5 (0.1) 1.8 Myocardial Infarction 1.2 (0.3) 1.8 Digestive Diarrhea 2.1 (0.1) 1.2 Nausea 1.3 (0.1) 0.6 Vomiting 1.3 (0.0) 0.9 Nervous/Psychiatric Dizziness 7.9 (0.6) 0.6 Headache 1.8 (0.1) 0.9 Vertigo 1.6 (0.1) 1.2 Respiratory Cough 2.2 (0.0) 0.6 Bronchitis 1.3 (0.0) 0.9 Dyspnea 1.3 (0.1) 0.4 Pneumonia 1.0 (0.0) 2.4 Skin Rash 1.3 (0.0) 2.4 Urogenital Urinary Tract Infection 1.3 (0.0) 2.4 Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in 0.5 to 1.0 percent of patients with hypertension or heart failure in clinical trials are listed below and, within each category, are in order of decreasing severity.

Body As A Whole: Anaphylactoid reactions (see WARNINGS, Anaphylactoid and Possibly Related Reactions). Cardiovascular: Cardiac arrest; myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients (see WARNINGS, Hypotension); pulmonary embolism and infarction; pulmonary edema; rhythm disturbances including atrial tachycardia and bradycardia; atrial fibrillation; palpitation, Raynaud’s phenomenon.

Digestive: Ileus, pancreatitis, hepatic failure, hepatitis (hepatocellular [proven on rechallenge] or cholestatic jaundice) (see WARNINGS, Hepatic Failure), melena, anorexia, dyspepsia, constipation, glossitis, stomatitis, dry mouth. Hematologic: Rare cases of neutropenia, thrombocytopenia and bone marrow depression. Musculoskeletal: Muscle cramps.

Nervous/Psychiatric: Depression, confusion, ataxia, somnolence, insomnia, nervousness, peripheral neuropathy (e.g., paresthesia, dysesthesia), dream abnormality. Respiratory: Bronchospasm, rhinorrhea, sore throat and hoarseness, asthma, upper respiratory infection, pulmonary infiltrates, eosinophilic pneumonitis. Skin: Exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, pemphigus, herpes zoster, erythema multiforme, urticaria, pruritus, alopecia, flushing, diaphoresis, photosensitivity.

Special Senses: Blurred vision, taste alteration, anosmia, tinnitus, conjunctivitis, dry eyes, tearing. Urogenital: Renal failure, oliguria, renal dysfunction (see PRECAUTIONS and DOSAGE AND ADMINISTRATION), flank pain, gynecomastia, impotence. Miscellaneous: A symptom complex has been reported which may include some or all of the following: a positive ANA, an elevated erythrocyte sedimentation rate, arthralgia/arthritis, myalgia/myositis, fever, serositis, vasculitis, leukocytosis, eosinophilia, photosensitivity, rash and other dermatologic manifestations.

Angioedema: Angioedema has been reported in patients receiving VASOTEC, with an incidence higher in black than in non-black patients. Angioedema associated with laryngeal edema may be fatal. If angioedema of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with VASOTEC should be discontinued and appropriate therapy instituted immediately (see WARNINGS, Head and Neck Angioedema).

Hypotension: In the hypertensive patients, hypotension occurred in 0.9 percent and syncope occurred in 0.5 percent of patients following the initial dose or during extended therapy. Hypotension or syncope was a cause for discontinuation of therapy in 0.1 percent of hypertensive patients. In heart failure patients, hypotension occurred in 6.7 percent and syncope occurred in 2.2 percent of patients.

Hypotension or syncope was a cause for discontinuation of therapy in 1.9 percent of patients with heart failure (see WARNINGS, Hypotension). Cough: See PRECAUTIONS, Cough. Pediatric Patients The adverse experience profile for pediatric patients appears to be similar to that seen in adult patients. Clinical Laboratory Test Findings Serum Electrolytes Hyperkalemia (see PRECAUTIONS, Hyperkalemia), hyponatremia.

Creatinine, Blood Urea Nitrogen In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.2 percent of patients with essential hypertension treated with VASOTEC alone. Increases are more likely to occur in patients receiving concomitant diuretics or in patients with renal artery stenosis (see PRECAUTIONS, Impaired Renal Function).

In patients with heart failure who were also receiving diuretics with or without digitalis, increases in blood urea nitrogen or serum creatinine, usually reversible upon discontinuation of VASOTEC and/or other concomitant diuretic therapy, were observed in about 11 percent of patients. Increases in blood urea nitrogen or creatinine were a cause for discontinuation in 1.2 percent of patients.

Hematology Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.3 g percent and 1.0 vol percent, respectively) occur frequently in either hypertension or congestive heart failure patients treated with VASOTEC but are rarely of clinical importance unless another cause of anemia coexists. In clinical trials, less than 0.1 percent of patients discontinued therapy due to anemia.

Hemolytic anemia, including cases of hemolysis in patients with G6PD deficiency, has been reported; a causal relationship to enalapril cannot be excluded. Liver Function Tests Elevations of liver enzymes and/or serum bilirubin have occurred (see WARNINGS, Hepatic Failure). To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Adverse reaction frequency tables (US label) US FDA label
VASOTEC (n=2314) Incidence (discontinuation)Placebo (n=230) Incidence
Body As A Whole
Fatigue3.0 (<0.1)2.6
Orthostatic Effects1.2 (<0.1)0.0
Asthenia1.1 (0.1)0.9
Digestive
Diarrhea1.4 (<0.1)1.7
Nausea1.4 (0.2)1.7
Nervous/Psychiatric
Headache5.2 (0.3)9.1
Dizziness4.3 (0.4)4.3
Respiratory
Cough1.3 (0.1)0.9
Skin
Rash1.4 (0.4)0.4
VASOTEC (n=673) Incidence (discontinuation)Placebo (n=339) Incidence
Body As A Whole
Orthostatic Effects2.2 (0.1)0.3
Syncope2.2 (0.1)0.9
Chest Pain2.1 (0.0)2.1
Fatigue1.8 (0.0)1.8
Abdominal Pain1.6 (0.4)2.1
Asthenia1.6 (0.1)0.3
Cardiovascular
Hypotension6.7 (1.9)0.6
Orthostatic Hypotension1.6 (0.1)0.3
Angina Pectoris1.5 (0.1)1.8
Myocardial Infarction1.2 (0.3)1.8
Digestive
Diarrhea2.1 (0.1)1.2
Nausea1.3 (0.1)0.6
Vomiting1.3 (0.0)0.9
Nervous/Psychiatric
Dizziness7.9 (0.6)0.6
Headache1.8 (0.1)0.9
Vertigo1.6 (0.1)1.2
Respiratory
Cough2.2 (0.0)0.6
Bronchitis1.3 (0.0)0.9
Dyspnea1.3 (0.1)0.4
Pneumonia1.0 (0.0)2.4
Skin
Rash1.3 (0.0)2.4
Urogenital
Urinary Tract Infection1.3 (0.0)2.4

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Enalapril and enalaprilat have been detected in human breast milk. Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue VASOTEC, taking into account the importance of the drug to the mother.

Mechanism of action

Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex.

The beneficial effects of enalapril in hypertension and heart failure appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium.

In hypertensive patients treated with VASOTEC alone for up to 48 weeks, mean increases in serum potassium of approximately 0.2 mEq/L were observed. In patients treated with VASOTEC plus a thiazide diuretic, there was essentially no change in serum potassium (see PRECAUTIONS). Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.

ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of VASOTEC remains to be elucidated. While the mechanism through which VASOTEC lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, VASOTEC is antihypertensive even in patients with low-renin hypertension.

Although VASOTEC was antihypertensive in all races studied, black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to enalapril monotherapy than non-black patients.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

Pharmacodynamics and Clinical Effects Hypertension Administration of VASOTEC to patients with hypertension of severity ranging from mild to severe results in a reduction of both supine and standing blood pressure usually with no orthostatic component. Symptomatic postural hypotension is therefore infrequent, although it might be anticipated in volume-depleted patients (see WARNINGS, Hypotension).

In most patients studied, after oral administration of a single dose of enalapril, onset of antihypertensive activity was seen at one hour with peak reduction of blood pressure achieved by four to six hours. At recommended doses, antihypertensive effects have been maintained for at least 24 hours. In some patients the effects may diminish toward the end of the dosing interval (see DOSAGE AND ADMINISTRATION, Hypertension).

In some patients achievement of optimal blood pressure reduction may require several weeks of therapy. The antihypertensive effects of VASOTEC have continued during long-term therapy. Abrupt withdrawal of VASOTEC has not been associated with a rapid increase in blood pressure. In hemodynamic studies in patients with essential hypertension, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in cardiac output and little or no change in heart rate.

Following administration of VASOTEC, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with renovascular hypertension. When given together with thiazide-type diuretics, the blood pressure lowering effects of VASOTEC are approximately additive.

In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC (see PRECAUTIONS, Drug Interactions). Heart Failure In trials in patients treated with digitalis and diuretics, treatment with enalapril resulted in decreased systemic vascular resistance, blood pressure, pulmonary capillary wedge pressure and heart size, and increased cardiac output and exercise tolerance.

Heart rate was unchanged or slightly reduced, and mean ejection fraction was unchanged or increased. There was a beneficial effect on severity of heart failure as measured by the New York Heart Association (NYHA) classification and on symptoms of dyspnea and fatigue. Hemodynamic effects were observed after the first dose and appeared to be maintained in uncontrolled studies lasting as long as four months.

Effects on exercise tolerance, heart size, and severity and symptoms of heart failure were observed in placebo-controlled studies lasting from eight weeks to over one year. Heart Failure, Mortality Trials In a multicenter, placebo-controlled clinical trial, 2,569 patients with all degrees of symptomatic heart failure and ejection fraction ≤35 percent were randomized to placebo or enalapril and followed for up to 55 months (SOLVD-Treatment).

Use of enalapril was associated with an 11 percent reduction in all-cause mortality and a 30 percent reduction in hospitalization for heart failure. Diseases that excluded patients from enrollment in the study included severe stable angina (>2 attacks/day), hemodynamically significant valvular or outflow tract obstruction, renal failure (creatinine >2.5 mg/dL), cerebrovascular disease (e.g., significant carotid artery disease), advanced pulmonary disease, malignancies, active myocarditis and constrictive pericarditis.

The mortality benefit associated with enalapril does not appear to depend upon digitalis being present. A second multicenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular ejection fraction ≤35% and no history of symptomatic heart failure, were randomized to placebo (n=2117) or enalapril (n=2111) and followed for up to 5 years.

The majority of patients in the SOLVD-Prevention trial had a history of ischemic heart disease. A history of myocardial infarction was present in 80 percent of patients, current angina pectoris in 34 percent, and a history of hypertension in 37 percent. No statistically significant mortality effect was demonstrated in this population.

Enalapril-treated subjects had 32% fewer first hospitalizations for heart failure, and 32% fewer total heart failure hospitalizations. Compared to placebo, 32 percent fewer patients receiving enalapril developed symptoms of overt heart failure. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect.

The SOLVD-Prevention trial was not designed to determine whether treatment of asymptomatic patients with low ejection fraction would be superior, with respect to preventing hospitalization, to closer follow-up and use of enalapril at the earliest sign of heart failure. However, under the conditions of follow-up in the SOLVD-Prevention trial (every 4 months at the study clinic; personal physician as needed), 68% of patients on placebo who were hospitalized for heart failure had no prior symptoms recorded which would have signaled initiation of treatment.

The SOLVD-Prevention trial was also not designed to show whether enalapril modified the progression of underlying heart disease. In another multicenter, placebo-controlled trial (CONSENSUS) limited to patients with NYHA Class IV congestive heart failure and radiographic evidence of cardiomegaly, use of enalapril was associated with improved survival.

The results are shown in the following table. Survival (%) Six Months One Year VASOTEC (n=127) 74 64 Placebo (n=126) 56 48 In both CONSENSUS and SOLVD-Treatment trials, patients were also usually receiving digitalis, diuretics or both.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Based on urinary recovery, the extent of absorption of enalapril is approximately 60 percent.

Excretion of VASOTEC is primarily renal.

The effective half-life for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours.

The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency (see DOSAGE AND ADMINISTRATION ).

Pharmacokinetics (US label) US FDA label

Pharmacokinetics and Metabolism Following oral administration of VASOTEC, peak serum concentrations of enalapril occur within about one hour. Based on urinary recovery, the extent of absorption of enalapril is approximately 60 percent. Enalapril absorption is not influenced by the presence of food in the gastrointestinal tract.

Following absorption, enalapril is hydrolyzed to enalaprilat, which is a more potent angiotensin-converting enzyme inhibitor than enalapril; enalaprilat is poorly absorbed when administered orally. Peak serum concentrations of enalaprilat occur three to four hours after an oral dose of enalapril maleate. Excretion of VASOTEC is primarily renal.

Approximately 94 percent of the dose is recovered in the urine and feces as enalaprilat or enalapril. The principal components in urine are enalaprilat, accounting for about 40 percent of the dose, and intact enalapril. There is no evidence of metabolites of enalapril, other than enalaprilat. The serum concentration profile of enalaprilat exhibits a prolonged terminal phase, apparently representing a small fraction of the administered dose that has been bound to ACE.

The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-life for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours. The disposition of enalapril and enalaprilat in patients with renal insufficiency is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less.

With glomerular filtration rate ≤30 mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases and time to steady state may be delayed. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of renal insufficiency (see DOSAGE AND ADMINISTRATION).

Enalaprilat is dialyzable at the rate of 62 mL/min. Studies in dogs indicate that enalapril crosses the blood-brain barrier poorly, if at all; enalaprilat does not enter the brain. Multiple doses of enalapril maleate in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration of 14 C-enalapril maleate.

Radioactivity was found to cross the placenta following administration of labeled drug to pregnant hamsters.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Enalapril 5 mg Tablet₱2.35–₱8.70Reference ₱2.86per tabletDPRI procurement range
Enalapril 20 mg Tablet₱3.00–₱9.60Reference ₱7.25per tabletDPRI procurement range
5 mg (as maleate) tablet₱6.00per tabletPhilHealth GAMOT fixed fee
20 mg (as maleate) tablet₱11.00per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Enalapril (as maleate)
PNF listingOral: 5 mg and 20 mg tablet
PhilHealth GAMOTYes (listed since July 28, 2025)
PhilHealth YAKAP (formerly Konsulta)Yes

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Vasotec · Bausch Health US LLC [US FDA-approved label, version 15, January 23, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39631f1f-5d19-43c1-b504-bf56d991ed97
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .